CD8A and neoplasm: The DC-stimulated CD8+ T cells were (1) challenged with either autologous ANRU tumor cells or an allogenic melanoma cell line KADA, both HLA-A2+, or (2) further expanded using a GMP-compatible rapid expansion (REP) protocol (2).